Olarewaju Bukola A, Tejon Judy B, Osundiji Mayowa A
School of Science and Engineering, University of Dundee, Nethergate, Dundee DD1 4HN, United Kingdom.
Department of Clinical Genomics, Mayo Clinic, East Shea Blvd, Scottsdale, AZ 85259, United States.
J Surg Case Rep. 2024 Oct 5;2024(10):rjae619. doi: 10.1093/jscr/rjae619. eCollection 2024 Oct.
With the increasing opportunities for medical management of von Hippel-Lindau (VHL)-related lesions, fundamental questions are arising regarding the possibilities of the FDA-approved medication (Belzutifan) to delay the progression of other non-VHL-related tumors that are not requiring urgent surgical interventions. We present a follow-up report on a VHL patient, with a co-morbid history of pulmonary mucosa-associated lymphoid tissue lymphoma, who was initially described in the clinical scientific literature ~10 years ago. This patient's case highlights some of the challenges for some VHL patients with comorbid non-VHL-related tumors and potential opportunities for targeted support.
随着对冯·希佩尔-林道（VHL）相关病变进行医学管理的机会不断增加，关于美国食品药品监督管理局（FDA）批准的药物（贝利尤单抗）能否延缓其他不需要紧急手术干预的非VHL相关肿瘤进展的基本问题也随之出现。我们提供了一份对一名VHL患者的随访报告，该患者患有肺黏膜相关淋巴组织淋巴瘤的合并病史，最初在约10年前的临床科学文献中有所描述。该患者的病例凸显了一些患有非VHL相关合并肿瘤的VHL患者所面临的挑战以及针对性支持的潜在机会。
